CURELAB ONCOLOGY

Investment Deck

curelaboncology.com
info@curelab.com
+1 (609) 841-1201

Safe Harbor Statement

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of the Private Securities Litigation reform Act of 1995, the Company notes that statements in this website, and elsewhere, that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations.

The following important factors could cause actual results to differ materially from those set forth in the forward-looking statements: project financing; new scientific findings; our products may not be accepted by the market; and we may have difficulty in hiring and retaining key personnel.

CureLab Oncology — overview

Breakthrough product

- Plasmid (circular DNA) coding p62 protein
- Over 130 patients enrolled in the studies
- Great safety profile

Focused on cancers in women

- Triple-negative (3NBC) and other forms of breast cancer
- Platinum-resistant ovarian cancer

Opportunities in other chronic inflammation diseases

Patents in more than 20 countries

Global professional team dedicated to helping patients



Clinical Trial Design

- **Primary endpoint: progression-free survival (PFS)**
  Progression-free survival is “the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.”

  A drug is considered effective if a patient group receiving the drug demonstrates PFS statistically significantly longer than a group receiving standard treatment.
  Elenagen has already demonstrated an increased PFS.

  Multiple drugs have received their market authorization from FDA and EMA based on increased PFS.
  We expect to demonstrate similar/exceeding PFS enhancement during our phase II FDA clinical trials.
  Some ex-US regulators are already ready to authorize Elenagen based on our current results.

- **Secondary endpoint: overall survival (OS)**
  The length of time the patients are alive from the start of cancer treatment. We expect Elenagen to increase OS compared to standard treatments.

- **Supplementary endpoint: quality of life (QoL)**
  While many cancer treatments make patients suffer, our studies observed the prolongation of patients’ normal life quality. Although not yet a generally accepted FDA/EMA criterion, we believe this will be a crucial factor in patients’ and doctors’ treatment of choice.

Platinum-Resistant Ovarian Cancer; Progression-Free Survival

Gemcitabine (20 patients, median 2.7 months) vs.
Gemcitabine + Elenagen (20 patients, median 7.2 months)



Patient B., 38 years old, right breast cancer, multifocal growth, metastases in the lymph nodes, right lung, and liver; therapy of Elenagen + CMF

Received 8 courses of CMF polychemotherapy plus Elenagen. A complete clinical response: disappeared metastases in the lungs, liver, lymph nodes, as well as a tumor

Before treatment 06/18/2020

After 6 courses CMF + Elenagen 01/18/2021



Radical surgical resection was performed. No living tumor cells were found in the removed tissue.

CURELAB ONCOLOGY

Comprehensive Patent Protection

Oncology patents

Granted

- Australia
- Chile
- Russia
- Belarus
- Belgium
- Switzerland
- Lichtenstein
- Germany
- Spain
- France
- UK
- Ireland
- Italy
- Luxembourg
- Netherlands
- Hong Kong
- Japan
- South Korea
- Mexico
- Singapore
- USA
- India

Pending

- Canada
- USA
- Brazil

Inflammation patents

Granted

- Australia
- Hong Kong
- Japan
- Singapore
- Belgium
- Switzerland
- Lichtenstein
- Germany
- France
- UK
- Luxembourg
- Monaco
- Netherlands
- Japan
- South Korea
- Mexico
- Singapore
- USA

Pending

- Canada
- China
- India
- South Korea
- USA
- Italy
- Spain

What makes our p62 IP fundamentally different from any other?

We did not patent p62 as a drug target.

Let others develop molecules targeting p62 and (most likely) fail with that approach.

Instead:

…on cancer applications

- We patented the use of a p62-encoding DNA/RNA as an anti-cancer agent.
- We patented the use of a p62-encoding DNA/RNA as an adjuvant to other cancer treatments.

…on diseases of chronic inflammation

- We patented the use of a p62-encoding DNA/RNA as an agent to treat non-cancerous diseases of chronic inflammation.
- We patented the use of a p62-encoding DNA/RNA as an agent to reduce levels of pro-inflammatory cytokines.
- We submitted a patent on utilizing a p62-encoding DNA/RNA as an agent to modulate stem cells (anti-aging effect).
- We submitted a patent on utilizing a p62-encoding DNA/RNA as an agent to treat COVID and reduce post-COVID complications.

Investment Opportunity

The global solid tumor market was estimated at US$121.3 B in 2018 and is expected to reach US$424.6 B by 2027, expanding at a CAGR of 15% from 2019 to 2027.



CureLab has only scratched the surface of the solid tumor market and the unmet medical needs of patients around the world.

	Market Size (2026-2028) in millions
Triple-negative breast cancer	$820
Platinum-resistant ovarian cancer	$6,700
Total solid tumor market	$424,600

Investment offer

Raising $25M on pre-money valuation of $100M
Anticipated time to ROI: 36 months from investment.

Use of proceeds

- Two new clinical trials in the US (FDA) + EU(EMA)
- Maintenance and extension of IP
- BD, out-licensing
- Exploratory clinical ex-USA

Previously raised

- More than $10M in cash and in-kind (mostly from ex-US governmental grants)

CURELAB ONCOLOGY

Mechanism of Action

- A simple intramuscular injection of a saline solution containing the p62 plasmid, Elenagen™
- Our plasmid enters the cells at the site of injection and remote (bone marrow)
- Cells with the plasmid express p62 and start sending signals to remote cells, tissues, and organs.
- The signaling induced by the plasmid reduces chronic inflammation



Expression Reduces Chronic Inflammation

Pro-Inflammatory Cytokines
(IL-1, L-6, TNF, etc…)

Chronic inflammation supports tumor progression, inhibits the immune responses against cancer and plays a role in lack/loss of response to chemotherapy

REDUCES
the pro-inflammatory cytokines (IL-1, L-6, TNF, etc…)

ENABLES BETTER
- Tumor Suppression
- Immune Responses
- Chemotherapeutic effect on cancer cells

Higher levels of Col3 in the tumor = positive disease prognosis



Evaluation of Col.I and Col 3 expression in tumor biopsies in tumor extracellular matrix
A. before
B. after p62 DNA treatment

Elenagen enhances anti-tumoral immune response

Elenagen enhances effect of adaptive T-cell transfer

CURELAB ONCOLOGY

Elenagen Stimulates MSCs

Elenagen acts on MSC remotely via a yet unknown signal

- Transfection of MSCs with p62 plasmid
- Transfection media is substituted with a fresh one w/o the plasmid

- Supernatant collected after 2 days
- Supernatant added to naïve MSCs



Anti-inflammatory cytokines are secreted by MSCs grown under the media collected from p62-transfected cell

Intramuscular injection of Elenagen

Propagation of unhealthy cell types (e.g. adipocytes)

Propagation of healthy cell types (e.g. osteoblasts)



MSC



Secretion of anti-inflammatory cytokines



Business Model



Primary strategy
Out-licensing to big pharma

- Up-front payment (dozens of $MM)
- Milestone payments (hundreds of $MM to $B)
- Percentage of royalties (hundred of $MM to $B)

Secondary strategy
IPO

- Go public (traditional path); SPAC

Supplemental strategy
Regional or disease-specific licensing

- Local licenses for each indication and geographic region
- Compassionate use

CURELAB ONCOLOGY

Clinical Program





CURELAB ONCOLOGY

Timing for Funding:

Why Now and Not Before?

- To secure a favorable pre-money valuation, we committed to commence raising money only when we had statistically significant proof of clinical benefits ($p<0.05$)
- COVID has slowed down patient enrollment and delayed our clinical study
- Finally, we have demonstrated clinical benefits for cancer patients ($p=0.01$)

Alex Shneider, PhD
Founder & CEO

25+ years biotech & entrepreneurial experience. Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and International Reviews of Immunology.

Vlad Gabai, PhD
VP of R&D

30+ years successful R&D experience for anti-cancer drugs. 80+ papers, 4,000+ references. Past academic appointments: Boston University and Boston Biomedical Research Institute.

Charles Legg
COO

20+ years biotech experience in program & portfolio management for rare diseases and oncology to startups for gene and cell therapy including two IPOs.

Ilya Lapshin, JD
General Council

18+ years in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Successful entrepreneur & co-founder with the sale of his company.

Franco Venanz,
Director Research

Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where was head of the Translational Biology Laboratory.

Ricarda Cramer, MBA
Director Business Development Europe

20+ years pharma and biotech experience in marketing, business development & portfolio management in big pharma companies.

Jihad A. Fakhreddine
Director Business Development

30+ years in healthcare, general management, business development, and fundraising

Stephen Spector
Director

30+ years in finance, M&A, raising money, private placements, IPOs, lending expertise as a director, sales and marketing.

CURELAB ONCOLOGY

Partnership with Gynecologic Oncology Group Foundation (GOG)

GOG is the leader in gynecologic cancer clinical trials

- Internationally recognized clinical experts
- Over 350 clinical trials
- Over 400 participating sites
- Over 115,000 patients

CureLab was selected by GOG for partnership

- GOG forms CureLab Advisory Board
- Assistance in FDA strategy and communication
- Assistance in the implementation of clinical trial in US
- Assistance with ex-US clinical studies (strategy and supervision)

First in-person CureLab-GOG Advisory Board meeting – 11/18/2022, Boston

Summary

Experienced and dedicated team

- Comprehensive set of proven track records

World-class advisory board

- 9th US Secretary of Veterans Administration
- World-leading professors
- Community experts

Unique mechanism of action of the lead product

- Changes tumor microenvironment
- Reduces chronic inflammation
- Enhances therapeutic benefits of other treatment modalities

Clinical data

- Excellent safety profile
- Statistically significant clinical benefits in on-going clinical trials

Comprehensive international IP protection

High anticipated ROI and short time to exit

CURELAB ONCOLOGY

Thank you!